The Ozempic Face Phenomenon

GLP-1 receptor agonists (semaglutide, tirzepatide) have 15M+ US prescriptions (2024). Dramatic weight loss (15-30% body weight) creates characteristic aesthetic side effects generating a new skincare category.

Ozempic Face Characteristics

• Volume loss: Hollowed cheeks, temples, orbits
• Skin laxity: Loose, sagging skin unable to contract
• Accelerated aging: Sudden wrinkles, fine lines, jowls
• Volume redistribution: Loss of facial definition
• Pre-mature aging: Often 5-10 years older appearance

Market Data

Search interest for Ozempic face grew 250%+ year-over-year (Google Trends 2025). Related searches: skin tightening, facial fillers, PDO threads all increased significantly.

OEM Product Opportunities

• HA dermal fillers: Most direct solution; OEM injectable products
• Topical plumping serums: HA + peptides for surface volume
• PN/PDRN skin boosters: For skin quality improvement
• Radiofrequency-compatible serums: For RF microneedling pairing
• Tightening creams: Peptides + retinoids + ceramides
• Hair loss serums: GLP-1 also causes telogen effluvium

Target Markets

Primary markets: USA (highest GLP-1 adoption), UK, Australia, UAE, Saudi Arabia — also highest aesthetic spending markets.